ZGNX - ゾゲニクス (Zogenix Inc.) ゾゲニクス

 ZGNXのチャート


 ZGNXの企業情報

symbol ZGNx
会社名 Zogenix Inc. (ゾゲニクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ゾゲニックス(Zogenix Inc.)は希少と他の中枢神経系(CNS)障害患者の特殊臨床ニーズを満たすCNS療法の開発・商業化に従事する製薬会社である。同社の治療中心分野はてんかん及び関連発作性疾患である。同社のリード製品候補であるZX008はドラベ症候群に関する発作性疾患治療のための低用量フェンフルラミンである。ZX008は米国・欧州連合(EU)において、ドラベ症候群の治療向けの希少疾患薬剤指定を受ける。同社は精神分裂症の治療のための追加製品候補でリスペリドンを1ヶ月に1回、長期間注射可能のReldayを有する。Reldayはリスペリドンの持続型注射製剤である。リスペリドンは、13歳以上の成人及びティーンエイジャーの統合失調症と双極性障害の症状を治療するために使用される。同社はReldayのフェーズIプログラムを完成した。   ゾゲニクスは米国の製薬会社。鎮痛剤および中枢神経障害治療薬の開発と商業化に従事。主な製品には偏頭痛治療の非侵襲性注射用キット「スマベルド―ズプロ(一般名:スマトリプタン)」、および24時間投与を長期間続ける必要がある重度疼痛用治療薬「ゾヒドロER(一般名:酒石酸水素ヒドロコドン徐放性カプセル)」などがある。   Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
本社所在地 5858 Horton Street Suite 455 Emeryville CA 94608 USA
代表者氏名 Cam L. Garner カム・L・ガーナー
代表者役職名 Independent Chairman of the Board
電話番号 +1 510-550-8300
設立年月日 38838
市場名 NASDAQ National Market System
ipoyear 2010年
従業員数 68人
url http://www.zogenix.com/
nasdaq_url https://www.nasdaq.com/symbol/zgnx
adr_tso
EBITDA EBITDA(百万ドル) -139.84600
終値(lastsale) 42.5
時価総額(marketcap) 1522644652.5
時価総額 時価総額(百万ドル) 1646.308
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 1374.205
当期純利益 当期純利益(百万ドル) -105.37700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Zogenix Inc. revenues decreased from $9.8M to $0K. Net loss before extraordinary items increased 35% to $59M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and develpoment increase of 77% to $48M (expense) Selling General_Administrative Exp increase of 30% to $13.4M (expense).

 ZGNXのテクニカル分析


 ZGNXのニュース

   Global Dravet Syndrome (DS) Market Analysis, Scope and Forecast By 2021-2027. The IBI Updates I Top key players-Ovid Therapeutics/Takeda, PTC Therapeutics and Zogenix & Others  2021/09/02 12:37:06 OpenPR
The research provided by Infinity Business Insights provides a thorough explanation of the disease as well as DS market trends in several locations. It examines multiple studies and the perspectives of important opinion leaders to assist identify the reasons of
   Zogenix gets orphan drug status for FINTEPLA in Japan  2021/08/26 12:25:52 Seeking Alpha
   Zogenix Receives Orphan Drug Designation for FINTEPLA® (Fenfluramine) in Japan  2021/08/26 12:00:00 Benzinga
Zogenix plans to submit a new drug application (J-NDA) for FINTEPLA in Japan for the treatment of seizures associated with Dravet syndrome by year end. Dravet syndrome is a rare, life-long form of epilepsy marked by severe seizures, significant developmental delays, frequent hospitalizations and medical emergencies, and increased risk of premature death . Seizures associated with Dravet syndrome are highly resistant to existing anti-epileptic medicines, pointing to a major need for new treatment options. EMERYVILLE, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX ), a global biopharmaceutical company developing rare disease therapies, today announced that the Japanese Ministry of Health, Labour & Welfare (MHLW) has granted Orphan Drug Designation to FINTEPLA® (fenfluramine) oral solution, which Zogenix is developing in Japan as a potential treatment for seizures associated with Dravet syndrome. Dravet syndrome is a rare infant- and childhood-onset epilepsy marked by frequent and severe treatment-resistant seizures, associated hospitalizations and medical emergencies, significant developmental and motor impairments, and an increased risk of sudden premature death.
   Fairmount Funds Management LLC Buys Instil Bio Inc, Zogenix Inc, Insmed Inc, Sells Mirati ...  2021/08/16 21:38:17 GuruFocus
Related Stocks: ZGNX , INSM , CATB , ARGX , AXSM , AMRN , TIL , RACA , MRTX , MCRB ,
   Zogenix Reports Granting of Inducement Awards  2021/08/16 21:02:00 Intrado Digital Media
EMERYVILLE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the companys board of directors granted inducement awards to fourteen new employees. The awards were made on August 15, 2021, under Zogenixs 2021 Employment Inducement Equity Incentive Award Plan, which was approved by the companys board of directors under Nasdaq Marketplace Rule 5635(c)(4), for granting equity awards to new employees of Zogenix as an inducement to join the company. The awards consist of options to purchase an aggregate of 34,580 shares of Zogenix common stock and 17,340 restricted stock units. The options have a ten year term and an exercise price equal to $13.75, the closing price per share of the common stock on August 13, 2021, and vest over a four-year period, with 25% of the options vesting on the first anniversary of each employees respective start date and the remainder vesting in equal monthly installments over the three years thereafter.
   Zogenix to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5  2021/07/22 12:00:00 Intrado Digital Media
EMERYVILLE, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will report its financial results for the second quarter ended June 30, 2021 and host a corporate update conference call and webcast after the market close on Thursday, August 5, 2021, at 4:30 PM Eastern Time.
   Zogenix: Await Q2 Fintepla Revenue, LGS Approval Before Jumping Back In  2021/07/21 11:29:35 Seeking Alpha
   Needle-Free Injection Device Market 2021 Segmentation by Clinical Areas- Zogenix, Inovio, Glide Pharma, Akra Dermojet, Crossject Medical Technology, Injex Pharma, Eternity Healthcare  2021/07/20 04:55:23 OpenPR
The Needle-Free Injection Device Market report is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection
   Zogenix Inc Shares Close in on 52-Week Low - Market Mover  2021/07/17 16:20:39 Kwhen Finance
Zogenix Inc (ZGNX) shares closed today at 1.6% above its 52 week low of $16.73, giving the company a market cap of $948M. The stock is currently down 15.0% year-to-date, down 41.1% over the past 12 months, and up 96.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 97.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 3.7% lower than its 5-day moving average, 4.6% lower than its 20-day moving average, and 8.5% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -389.6% The company's stock price performance over the past 12 months lags the peer average by -492.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Zogenix Inc Shares Approach 52-Week Low - Market Mover  2021/07/17 02:21:46 Kwhen Finance
Zogenix Inc (ZGNX) shares closed today at 100.0% below its 52 week low of $16.73, giving the company a market cap of $948M. The stock is currently down 15.0% year-to-date, down 41.3% over the past 12 months, and up 98.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 6.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -389.6% The company's stock price performance over the past 12 months lags the peer average by -532.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies  2020/12/03 22:42:00 Benzinga
CAMBRIDGE, Mass. and EMERYVILLE, Calif. , Dec. 3, 2020 /PRNewswire/ -- Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix (NASDAQ: ZGNX ), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that the companies have entered into a collaboration to identify and develop novel tRNA-based gene therapies for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will utilize its two unique tRNA-based discovery platforms focused on mRNA Stabilization and Nonsense Codon Suppression to discover and advance novel drug candidates for the treatment of Dravet syndrome and other genetic epilepsies. Zogenix will further develop the candidates through advanced preclinical studies and clinical development, and be responsible for worldwide commercialization. Zogenix is responsible for funding the collaboration and, under the terms of the agreement, Tevard will receive an initial collaboration payment of $10 million , of which approximately $5 million has previously been paid by Zogenix.
   Needle Free Diabetes Care Market With Leading Players like Zogenix, 3M, Antares Pharma, Glide Pharmaceutical Technologies Ltd., Injex Pharma AG, Pharmajet, Bioject Medical Technologies, Medtronic, Johnson and Johnson, Pancreum LLC  2020/11/24 05:27:59 OpenPR
An off-the-shelf report on Needle Free Diabetes Care Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market
   Cerebral Therapeutics Appoints Stephen J. Farr as Chairman and Welcomes Stephen D. Collins to the Board of Directors  2020/11/10 16:00:00 Business Wire
AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological diseases, has appointed Stephen J. Farr, PhD as Chairman of the board of directors. Dr. Farr is the Co-Founder, President, and Chief Executive Officer of Zogenix, a biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. “Dr
   Zogenix Provides Corporate Update and Reports Third Quarter 2020 Financial Results  2020/11/09 21:01:00 GlobeNewswire
FINTEPLA® (fenfluramine) oral solution launched in the U.S. in late July for Dravet syndrome with high enrollment of physicians and patients into the…
   Zogenix, Inc. (NASDAQ:ZGNX) Short Interest Update  2020/10/21 06:50:42 Dakota Financial News
Zogenix, Inc. (NASDAQ:ZGNX) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 6,690,000 shares, an increase of 23.4% from the September 15th total of 5,420,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is currently […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ゾゲニクス ZGNX Zogenix Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)